Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Bioscience Caucus briefed on next steps for CT

State Senator Christine Cohen and the Connecticut legislature’s Bioscience Caucus were briefed this week by a private-sector bioscience industry advocate and by the commissioner of Connecticut’s...

| By Kelley Gipson

QCDx sells RareScope™ instrument to UConn Health

QCDx, a private biotech company based in Farmington, CT that has developed a breakthrough Circulating Tumor Cell (CTC) liquid biopsy from a simple blood draw,...

| By Kelley Gipson

CT pushing to develop ‘hubs of innovation’

David Lehman, the state’s commissioner of economic and community development, said there will be a strong push to create hubs of innovation in industries such...

| By Kelley Gipson

Lamont announces new CT business assistance

Connecticut Governor Ned Lamont has announced that the first proposals he is submitting to the Connecticut General Assembly during the 2020 legislative session will be a...

| By Kelley Gipson

JAX in research agreement with Shriners Hospitals

With the goal of identifying advanced treatment approaches for children with genetic orthopedic conditions, Shriners Hospitals for Children® and The Jackson Laboratory (JAX) have entered...

| By Kelley Gipson

Winstanley plans lab space project for New Haven

A prominent developer is proposing to build 500,000 square feet of laboratory and life-sciences incubation space in downtown New Haven. Winstanley Enterprises LLC plans a major...

| By Kelley Gipson

New Haven’s Wellinks to be acquired by Convexity

Wellinks, a six-year-old New Haven startup founded by Yale students who invented an internet-connected brace-monitoring strap for scoliosis patients, has been acquired by Fairfield respiratory...

| By Kelley Gipson

Alexion plans Phase 3 Study Of ULTOMIRIS® re ALS

Alexion Pharmaceuticals is planning to initiate a pivotal Phase 3 study of ULTOMIRIS® (ravulizumab) in amyotrophic lateral sclerosis (ALS). The 50-week global study, called CHAMPION-ALS,...